An announcement from MaxCyte ( (MXCT) ) is now available.
MaxCyte, Inc. announced the vesting of 20,313 restricted stock units (RSUs) to its Chief Financial Officer, Douglas Swirsky, with 6,939 shares sold to cover withholding taxes. This transaction, which does not represent a discretionary trade, highlights the company’s ongoing commitment to aligning executive compensation with shareholder interests. The sale of shares, representing a small portion of Mr. Swirsky’s holdings, is part of routine financial management and reflects the company’s transparent approach to executive dealings.
More about MaxCyte
MaxCyte, Inc. is a leading company in the cell-engineering industry, focusing on providing platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics. The company offers the ExPERT™ platform, which utilizes Flow Electroporation® technology to support the cell therapy market, covering the entire spectrum from discovery to commercialization. MaxCyte’s product suite includes instruments, processing assemblies, and software protocols, all backed by a strong intellectual property portfolio, aiming to transform human health.
YTD Price Performance: -25.93%
Average Trading Volume: 39,949
Technical Sentiment Signal: Strong Buy
Current Market Cap: £258M
See more data about MXCT stock on TipRanks’ Stock Analysis page.